Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives $22.17 Consensus Target Price from Brokerages
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has been given an average rating of “Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the […]
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT – Get Free Report) has been given an average rating of “Buy” by the six analysts that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating on the […]
